Yahoo Finance

Operations: The company's revenue is derived from its biotechnology startups segment, totaling $45.67 million.

Market Cap: $164.2M

Protalix BioTherapeutics, with a market cap of US$164.20 million, is navigating the challenges typical of penny stocks in the biotech sector. Despite being unprofitable, it has shown improvement by reducing losses over the past five years and maintaining a stable cash runway for over three years due to positive free cash flow. The company's recent earnings report revealed a revenue increase to US$17.96 million in Q3 2024 from US$10.35 million year-over-year, marking progress despite an overall net loss for the nine months ending September 2024. Protalix's seasoned management and board bolster its strategic direction amidst industry volatility.

• Click to explore a detailed breakdown of our findings in Protalix BioTherapeutics' financial health report.

• Assess Protalix BioTherapeutics' future earnings estimates with our detailed growth reports.

Tecogen

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Tecogen Inc. designs, manufactures, markets, and maintains ultra-clean cogeneration products for various sectors primarily in the United States, with a market cap of approximately $46.47 million.

Operations: The company's revenue is derived from three main segments: Products ($4.77 million), Services ($15.95 million), and Energy Production ($2.09 million).

Market Cap: $46.47M

Tecogen Inc., with a market cap of US$46.47 million, faces challenges common among penny stocks, such as unprofitability and declining earnings over the past five years. Despite this, Tecogen's recent client announcements highlight potential growth opportunities through orders for cogeneration systems and chillers in key projects like the Las Vegas Convention Center. The company maintains a stable financial position with short-term assets exceeding liabilities and has sufficient cash runway for more than three years if free cash flow continues to grow. However, its high share price volatility and increased debt-to-equity ratio remain concerns for investors.

• Navigate through the intricacies of Tecogen with our comprehensive balance sheet health report here.

• Learn about Tecogen's historical performance here.

Turning Ideas Into Actions

• Get an in-depth perspective on all 724 US Penny Stocks by using our screener here.

• Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments.

• Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide.

Looking For Alternative Opportunities?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.

• Jump on the AI train with fast growing tech companies forging a new era of innovation.

• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NasdaqCM:ARBE NYSEAM:PLX and OTCPK:TGEN.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com